ArticleTranslational cancer research2026
Parimifasor elicits broad-spectrum antitumor effects by suppressing the expression of oncogenic genes.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cancer remains a leading cause of death worldwide, constrained by limitations of current therapies, such as systemic toxicity, narrow therapeutic windows, and acquired drug resistance, highlighting the urgent need for novel agents. This study aimed to evaluate the antitumor efficacy of parimifasor and elucidate its molecular mechanism through transcriptomic profiling. Methods: This study evaluated the efficacy of parimifasor Results: This study presents the first mechanistic exploration of the small-molecule immunomodulator parimifasor (CAS: 1796641-10-5) as a broad-spectrum antitumor agent. Conclusions: This study establishes parimifasor's antitumor efficacy via the suppression of immune pathway-associated oncogenes, supporting its repurposing as a cancer therapeutic agent and providing biomarker candidates for clinical development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.